Skip to main content

Advertisement

Log in

Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

Neoadjuvant therapy (NAT) for pancreatic adenocarcinoma (PDAC) patients has shown promising results in non-randomized trials. This is a multi-institutional phase II trial of NAT in resectable PDAC patients.

Methods

Patients with confirmed resectable PDAC after agreement by two expert radiologists were eligible. Patients received three cycles of GEM (1000 mg/m2/week) plus daily erlotinib (ERL) (100 mg/day). After re-staging, patients without progressive disease underwent 5 weeks of therapy with GEM (300 mg/m2/week), ERL 100 mg/day and concomitant radiotherapy (45 Gy). Efficacy was assessed using tumor regression grade (TRG) and resection margin status. Using a single-arm Simon’s design, considering the therapy not useful if R0 < 40% and useful if the R0 > 70% (alpha 5%, beta 10%), 24 patients needed to be recruited. This trial was registered at ClinicalTrials.gov, number NCT01389440.

Results

Twenty-five patients were enrolled. Adverse effects of NAT were mainly mild gastrointestinal disorders. Resectability rate was 76%, with a R0 rate of 63.1% among the resected patients. Median overall survival (OS) and disease-free survival (DFS) were 23.8 (95% CI 11.4–36.2) and 12.8 months (95% CI 8.6–17.1), respectively. R0 resection patients had better median OS, compared with patients with R1 resection or not resected (65.5 months vs. 15.5 months, p = 0.01). N0 rate among the resected patients was 63.1%, and showed a longer median OS (65.5 vs. 15.2 months, p = 0.009).

Conclusion

The results of this study confirm promising oncologic results with NAT for patients with resectable PDAC. Therefore, the present trial supports the development of phase II randomized trials comparing NAT vs. upfront surgery in resectable pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Varadhachary GR, Wolff RA, Crane CH et al (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487–3495

    Article  CAS  Google Scholar 

  2. OʼReilly EM, Perelshteyn A, Jarnagin WR et al (2014) A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 260:142–148

    Article  Google Scholar 

  3. Heinrich S, Schäfer M, Weber A et al (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248:1014–1022

    Article  Google Scholar 

  4. White RR, Hurwitz HI, Morse MA et al (2001) Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 8:758–765

    Article  CAS  Google Scholar 

  5. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89:314–327

    Article  CAS  Google Scholar 

  6. Talamonti MS, Small W, Mulcahy MF et al (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13:150–158

    Article  Google Scholar 

  7. Pipas JM, Barth RJ, Zaki B et al (2005) Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 12:995–1004

    Article  Google Scholar 

  8. Golcher H, Brunner TB, Witzigmann H et al (2015) Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 191:7–16

    Article  Google Scholar 

  9. Evans DB, Varadhachary GR, Crane CH et al (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3496–3502

    Article  CAS  Google Scholar 

  10. Joensuu TK, Kiviluoto T, Kärkkäinen P et al (2004) Phase I–II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60:444–452

    Article  CAS  Google Scholar 

  11. Duffy A, Kortmansky J, Schwartz GK et al (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol Off J Eur Soc Med Oncol 19:86–91

    Article  CAS  Google Scholar 

  12. Maurel J, Martin-Richard M, Conill C et al (2006) Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 66:1391–1398

    Article  CAS  Google Scholar 

  13. Gómez-Mateo MDC, Sabater-Ortí L, Ferrández-Izquierdo A (2014) Pathology handling of pancreatoduodenectomy specimens: approaches and controversies. World J Gastrointest Oncol 6:351–359

    Article  Google Scholar 

  14. Esposito I, Kleeff J, Bergmann F et al (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660

    Article  Google Scholar 

  15. Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathol Correl Cancer 73:2680–2686

    CAS  Google Scholar 

  16. Xia BT, Fu B, Wang J et al (2017) Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? J Surg Oncol 115:376–383

    Article  CAS  Google Scholar 

  17. Youngwirth LM, Nussbaum DP, Thomas S et al (2017) Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18243 patients. J Surg Oncol 116:127–132

    Article  CAS  Google Scholar 

  18. Mirkin KA, Hollenbeak CS, Wong J (2016) Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. Int J Surg 34:96–102

    Article  Google Scholar 

  19. Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G (2016) Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer—a case report and review. BMC Cancer 16:786

    Article  Google Scholar 

  20. Hackert T, Sachsenmaier M, Hinz U et al (2016) Locally advanced pancreatic cancer—neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg 264:1

    Article  Google Scholar 

  21. Blaze M, Wu C, Goldberg RM et al (2015) Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 22:1153–1159

    Article  Google Scholar 

  22. Petrelli F, Coinu A, Borgonovo K et al (2015) FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas 44:515–521

    Article  CAS  Google Scholar 

  23. Lee JH, Kang CM, Bang SM et al (2015) The role of neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic cancer with isolated venous vascular involvement. Medicine (Baltimore) 94:e1233

    Article  CAS  Google Scholar 

  24. Schneitler S, Kröpil P, Riemer J et al (2015) Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World J Gastroenterol 21:6384–6390

    Article  Google Scholar 

  25. Miura JT, Krepline AN, George B et al (2015) Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery 158:1545–1555

    Article  Google Scholar 

  26. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16:317–323

    Article  CAS  Google Scholar 

  27. Youngwirth LM, Nussbaum DP, Thomas S et al (2017) Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18,243 patients. J Surg Oncol 116:127–132

    Article  CAS  Google Scholar 

  28. Shubert CR, Bergquist JR, Groeschl RT et al (2016) Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database. Surgery (United States) 160:1080–1096

    Google Scholar 

  29. Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277

    Article  CAS  Google Scholar 

  30. Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. JAMA 304:1073

    Article  CAS  Google Scholar 

  31. Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024

    Article  CAS  Google Scholar 

  32. O’Reilly EM, Perelshteyn A, Jarnagin WR et al (2014) A single-arm, non-randomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 260:142–148

    Article  Google Scholar 

  33. Mokdad AA, Minter RM, Zhu H et al (2017) Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 35:515–522

    Article  Google Scholar 

  34. D’Angelo FA, Antolino L, La Rocca M et al (2016) Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials. Med Oncol 33:1–9

    Article  CAS  Google Scholar 

  35. Katz MHG, Shi Q, Ahmad SA et al (2016) Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg 151:e161137

    Article  Google Scholar 

  36. Hammel P, Huguet F, van Laethem J-L et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853

    Article  CAS  Google Scholar 

  37. Collisson EA, Sadanandam A, Olson P et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17:500–503

    Article  CAS  Google Scholar 

  38. Feig C, Jones JO, Kraman M et al (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110:20212–20217

    Article  CAS  Google Scholar 

  39. Gunderson AJ, Kaneda MM, Tsujikawa T et al (2016) Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov 6:270–285

    Article  CAS  Google Scholar 

  40. Mace TA, Ameen Z, Collins A et al (2013) Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73:3007–3018

    Article  CAS  Google Scholar 

  41. Steele CW, Karim SA, Leach JDG et al (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29:832–845

    Article  CAS  Google Scholar 

  42. Yang X, Lin Y, Shi Y et al (2016) FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res 76:4124–4135

    Article  CAS  Google Scholar 

  43. Kalbasi A, Komar C, Tooker GM et al (2017) Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin Cancer Res 23:137–148

    Article  CAS  Google Scholar 

  44. Mitchem JB, Brennan DJ, Knolhoff BL et al (2013) Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 73:1128–1141

    Article  CAS  Google Scholar 

  45. Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP (2010) CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 103:1671–1679

    Article  CAS  Google Scholar 

  46. Nywening TM, Wang-Gillam A, Sanford DE et al (2016) Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651–662

    Article  CAS  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Joan Maurel or Laureano Fernández-Cruz.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study are in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maurel, J., Sánchez-Cabús, S., Laquente, B. et al. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). Cancer Chemother Pharmacol 82, 935–943 (2018). https://doi.org/10.1007/s00280-018-3682-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-018-3682-9

Keywords

Navigation